SCHEMBL5774049

SCHEMBL5774049

COc1nc2ccccc2[nH]c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAUR Q03405 1/20 0.56
KDM4E B2RXH2 12/20 0.56
RAB9A P51151 6/20 0.53
NPC1 O15118 5/20 0.53
ALDH1A1 P00352 8/20 0.51
KHK P50053 1/20 0.51
HSD17B10 Q99714 3/20 0.51
HPGD P15428 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MAPK10 P53779 1/20 0.50
POLB P06746 1/20 0.50
MAPT P10636 2/20 0.49
TP53 P04637 1/20 0.49
ALOX15 P16050 1/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
HTT P42858 3/20 0.49
PKM P14618 1/20 0.49
GAA P10253 1/20 0.49
PYGM P11217 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6687302 0.79 PLAUR (0.53) PLAURKDM4ERAB9ANPC1ALDH1A1
SCHEMBL11365151 0.79 PLAUR (0.53) PLAURKDM4ERAB9ANPC1ALDH1A1
SCHEMBL8755403 0.78 HPGD (0.55) PLAURKDM4ERAB9ANPC1ALDH1A1
SCHEMBL6687300 0.77 PLAUR (0.50) PLAURKDM4ERAB9ANPC1ALDH1A1
SCHEMBL5770150 0.77 EGFR (0.55) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL5769991 0.77 HRH4 (0.52) ALDH1A1MAPTMEN1KMT2AHRH4
SCHEMBL1589916 0.76 PLAUR (0.61) PLAURKDM4ERAB9ANPC1ALDH1A1
SCHEMBL30617972 0.76 PLAUR (0.61) PLAURKDM4ERAB9ANPC1ALDH1A1
SCHEMBL5772298 0.75 PARP1 (0.45) KDM4EALDH1A1HSD17B10HPGD
SCHEMBL28139940 0.75 PLAUR (0.51) PLAURKDM4ERAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670774-A1 QUINOXALINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-21 EP disclosed
WO-2005033088-A1 QUINOXALINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2005-04-14 WO disclosed
US-20050070527-A1 For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070527-A1 For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions HRH4, HRH3, LTB4R PLAUR 176/4885KDM4E 2545/4885RAB9A 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.